GC Cell Corporation (KOSDAQ:144510)

Market Cap	380.19B +17.4%
Revenue (ttm)	170.13B -7.7%
Net Income	-98.19B
EPS	-6,534.81
Shares Out	15.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,688
Average Volume	64,665
Open	25,700
Previous Close	24,500
Day's Range	24,800 - 25,800
52-Week Range	16,940 - 28,450
Beta	0.72
RSI	52.08
Earnings Date	Feb 6, 2026

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 698
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2024, GC Cell's revenue was 174.45 billion, a decrease of -6.98% compared to the previous year's 187.54 billion. Losses were -73.90 billion, 42368.9% more than in 2023.